Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial
نویسندگان
چکیده
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99] P. Albers*, S.-I. Park, G. Niegisch, G. Fechner, U. Steiner, J. Lehmann, D. Heimbach, A. Heidenreich, R. Fimmers & R. Siener for the AUO Bladder Cancer Group Department of Urology, Düsseldorf University, Düsseldorf; Department of Urology, Bonn University, Bonn; Department of Urology, Charité University Berlin, Berlin; Department of Urology, Homburg University, Homburg; Department of Urology, St. Vincenz Hospital, Datteln; Department of Urology, Aachen University, Aachen; Institute of Medical Biometry, Informatics and Epidemiology, Bonn University, Bonn, Germany
منابع مشابه
Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls.
editorial Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls Few randomized clinical trials have been conducted in first-line setting and even fewer in the second-line setting in advanced bladder cancer. Overall, patients' impaired renal function, poor performance status (PS), advanced age and comorbidities have limited trial ...
متن کاملResponse to neoadjuvant chemotherapy in locally advanced gastric and gastroesophageal cancer: Phase II clinical trial
Background: Gastric cancer is an important health problem across the world. Chemotherapy in combination with local treatment is standard treatment for locally advanced gastroesophageal cancers. The purpose of this investigation was evaluation of response and tolerability to neoadjuvant EOX regimen in locoregionally advanced gastric cancer. Materials and Methods: patients with locoregionally adv...
متن کاملSecond-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).
OBJECTIVE The efficacy of second-line treatment after failure of platinum-based chemotherapy in patients with advanced urothelial cancer is limited. Based on encouraging preclinical and clinical phase I data, we evaluated the safety and efficacy of the combination of paclitaxel and everolimus in these patients. METHODS In this trial, patients having failed to respond to prior platinum-based c...
متن کاملA phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial.
BACKGROUND We sought to determine whether the substantial benefits of topical nitroglycerin with first-line, platinum-based, doublet chemotherapy in advanced nonsmall-cell lung cancer (NSCLC) seen in a phase II trial could be corroborated in a rigorous, multicenter, phase III trial. PATIENTS AND METHODS Patients starting one of five, prespecified, platinum-based doublets as first-line chemoth...
متن کاملPhase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
BACKGROUND Triple-negative breast cancer is an aggressive disease with unmet clinical needs. In a phase III study of patients with metastatic triple-negative breast cancer, first-line gemcitabine/carboplatin resulted in a median progression-free survival of 4.6 months. nab-paclitaxel-based regimens (with gemcitabine or carboplatin±bevacizumab) also demonstrated efficacy and safety in first-line...
متن کامل